Geron Corporation
LSE: 0IV3.L0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- London Stock Exchange
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- CEO
- Harout Semerjian
- Employees
- 229
- Headquarters
- Foster City, United States
- IPO year
- 2018
- Market cap
- $960.6M
- Website
- https://www.geron.com
Loading 0IV3…
Loading profile data…Frequently asked questions about 0IV3
What does Geron Corporation (0IV3.L) do?
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hemat...
Where does 0IV3.L trade?
Geron Corporation (0IV3.L) trades on the London Stock Exchange.
What sector is 0IV3.L in?
Geron Corporation (0IV3.L) operates in the Healthcare sector, specifically in the Medical - Pharmaceuticals industry.
Who is the CEO of Geron Corporation?
Harout Semerjian is the chief executive officer of Geron Corporation (0IV3.L).
Where is Geron Corporation headquartered?
Geron Corporation is headquartered in United States.
Does 0IV3.L pay a dividend?
Geron Corporation (0IV3.L) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 0IV3.L go public?
Geron Corporation (0IV3.L) completed its initial public offering in 2018.